Sector Expert: Michael Higgins
Michael Higgins is a senior life sciences analyst at Highline Research Advisors LLC. Prior to that he was Brinson Patrick Securities' first analyst and established the research platform. Prior to joining Brinson Patrick, Higgins was a managing director and senior specialty pharmaceuticals analyst at Rodman & Renshaw. Prior to joining Rodman & Renshaw, Higgins gained 10 years of drug marketing experience with Procter & Gamble Pharmaceuticals, followed by 12 years as a research analyst. He has worked as an analyst with Dafna Capital Management, Wedbush Securities and an independent research firm he founded, 4sight Research Partners. Higgins has earned a four-star rating from StarMine for stock recommendation performance. He is most recognized for his coverage of "drug launch" companies, as well as drug delivery technologies and patents. Higgins received his bachelor's degree in finance from the University of Wisconsin and his master's of business administration from Marquette University.
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island. The most fabulous fundamentals in the world won't propel a stock against powerful global or industry-wide headwinds. In this interview with The Life Sciences Report, Higgins, an industry veteran, discusses his methods of finding winning plays in the biotech space, and selects three names that could spike the punch in your portfolio.
A bit of luck and a lot of capital: Drug companies need both to navigate the seemingly perpetual path leading to the market debut of a new drug. Brinson Patrick Securities Managing Director Michael Higgins uses his experience as a drug marketer with big pharma to identify investment opportunities in companies with new drugs that address unmet needs. Higgins serves up his very best ideas to The Life Sciences Report and explains in detail why four growth stocks can rack up huge gains for investors gutsy enough to bet on smaller companies.